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1. Which of the following techniques have been used to characterize molecular biomarkers in patients with non–
small cell lung cancer (NSCLC)? 
a. Microarrays   
b. Reverse-transcription polymerase chain reaction 
c. Immunohistochemistry 
d. Fluorescence in situ hybridization 
e. All of the above 
2. Variations in these aspects can cause antibody-based detection methods to yield inconsistent results, EXCEPT 
for which of the following? 
a. Antibody production batch 
b. Staining protocol 
c. Cutoff criteria 
d. Scoring method 
e. None of the above 
3. Which of the following biomarkers are being examined as tools to guide chemotherapy selection in patients with 
NSCLC?
a. ERCC1 
b. KRAS  
c. Epidermal growth factor receptor (EGFR) 
d. All of the above 
e. None of the above 
4. What is the role of RRM1? 
a. RRM1 is an excision nuclease involved in repairing platinum-induced DNA damage. 
b. RRM1 regulates an enzyme that catalyzes deoxynucleotide production. 
c. RRM1 maintains intracellular levels of thymidine. 
d. Both a and b 
e. None of the above 
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5. Which of the following theories were evaluated in the phase II prospective MADeIT study? 
a. Patients with high ERCC1 levels are more likely to receive benefit from platinum-based regimens.
b. Patients with low ERCC1 levels are more likely to receive benefit from platinum-based regimens. 
c. Patients with high RRM1 levels are more likely to receive benefit from gemcitabine-based regimens. 
d. Patients with low RRM1 levels are more likely to receive benefit from gemcitabine-based regimens. 
e. Both b and d 
6. Models predicting risk of tumor recurrence can be developed from which of the following types of datasets? 
a. Clinical factors and gene expression 
b. Genome-wide expression profiles 
c. MicroRNA expression profiles 
d. All of the above 
e. None of the above 
7. In patients with NSCLC, which of the following clinical characteristics have been associated with response to 
EGFR–tyrosine kinase inhibitor (TKI) therapy? 
a. Ever-smoker status 
b. Male gender 
c. Asian ethnicity 
d. Patients with squamous cell carcinoma histologies 
e. None of the above 
8. In patients with NSCLC, which of the following biomarkers may have a role in predicting response to EGFR 
inhibitors?
a. EGFR protein expression 
b. Mutations in EGFR 
c. Increased EGFR gene copy number 
d. All of the above 
e. Both a and b only 
9. Which of the following clinical trials investigated the efficacy of an EGFR inhibitor in a population of relatively 
unselected patients with NSCLC? 
a. BMS-099 
b. FLEX 
c. IPASS 
d. ONCOBELL 
e. None of the above 
10. Which of the following characteristics accurately describe the ongoing BATTLE trial? 
a. The BATTLE trial uses an adaptive randomization design. 
b. Biomarker profiles are used to select patients for treatment. 
c. Patients are more likely to be randomized to an effective chemotherapy arm. 
d. All of the above 
e. Both a and b only 
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